Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially representing a new avenue for treating Alzheimer’s disease.
Vigil Neuroscience has reported early clinical data on its Alzheimer’s disease candidate, positioning the biotech to advance its small molecule in the footsteps of AbbVie and Alector’s failed rival ...
A candlelight vigil will be held on Monday evening, Jan. 20 for the man who was killed in a three-vehicle crash that happened last week in Northeast El Paso. The vigil will be held for Cody Vaughn, 31 ...
Results that may be inaccessible to you are currently showing.